Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CV Sciences (CVSI) Shares Outstanding (Diluted Average) (2017 - 2025)

CV Sciences' Shares Outstanding (Diluted Average) history spans 9 years, with the latest figure at $184.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 4.94% to $184.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $184.3 million, a 4.94% increase, with the full-year FY2025 number at $184.3 million, up 4.94% from a year prior.
  • Shares Outstanding (Diluted Average) hit $184.3 million in Q4 2025 for CV Sciences, roughly flat from $184.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CVSI hit a ceiling of $184.3 million in Q1 2025 and a floor of $104.5 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $149.0 million across 5 years, with a median of $152.6 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 30.19% in 2023 and later increased 1.1% in 2025.
  • Tracing CVSI's Shares Outstanding (Diluted Average) over 5 years: stood at $107.8 million in 2021, then grew by 28.03% to $138.0 million in 2022, then grew by 10.92% to $153.1 million in 2023, then rose by 14.68% to $175.6 million in 2024, then increased by 4.94% to $184.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CVSI at $184.3 million in Q4 2025, $184.3 million in Q3 2025, and $184.3 million in Q2 2025.